Q-omics provides the consensus-scored TMEM170A profile across patient tissues and cancer cell-line models. TMEM170A expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM170A is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, TMEM170A RNA expression shows 21,162 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where TMEM170A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM170A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM170A survival associations across molecular data types. TMEM170A RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM170A RNA expression–survival associations across cancer types. High TMEM170A expression shows unfavorable associations in LUSC, but favorable associations in KIRC, READ, UCS, SKCM and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM170A RNA expression.
This table summarizes TMEM170A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM170A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM170A shows lower tumor expression in THCA, LUSC and BRCA and higher tumor expression in STAD, BLCA and HNSC. The THCA box plot shows higher TMEM170A RNA expression in normal versus tumor tissue (log2 FC = −0.472, t-test p < 0.001).
This table shows molecular features associated with TMEM170A in patient tissues and cancer cell lines. In patient samples, TMEM170A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM170A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
